<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872155</url>
  </required_header>
  <id_info>
    <org_study_id>NICIR</org_study_id>
    <nct_id>NCT02872155</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephropathy (CIN) in Patients With Renal Insufficiency (RI) Grade III Under Study Conducting Computed Tomography (CT)</brief_title>
  <acronym>NICIR</acronym>
  <official_title>Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephropathy (CIN) in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Garcia Cinca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates if oral hydratation is as effective as endovenous hydratation in the
      prophylaxis of contrast-induced nephropathy in patients renal insufficiency grade III under
      study conducting contrasted computed tomography.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of contrast induced nephropathy</measure>
    <time_frame>48-72 hours after the completion of the computed tomography</time_frame>
    <description>Contrast induced nephropathy defined as a creatinine increase&gt; 0.5 mg
/ dl comparing the initial blood test to the blood test performed after 48-72 hours to the completion of the computed tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for hemodialysis</measure>
    <time_frame>15 days</time_frame>
    <description>Need for hemodialysis for one month after completion of the computed tomography, among patients who have undergone oral or intravenous hydration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reversibility of contrast induced nephropathy</measure>
    <time_frame>15 days</time_frame>
    <description>Defined as no increase in creatinine&gt; 0.5 mg / dl compared to the initial analysis performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse events</measure>
    <time_frame>15 days</time_frame>
    <description>Presence of adverse events, grade 3 adverse events and serious adverse events related to the investigational products during the study follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Oral hydratation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovenous hydratation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral hydratation</intervention_name>
    <description>500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography</description>
    <arm_group_label>Oral hydratation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicarbonate endovenous hydratation</intervention_name>
    <description>Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.</description>
    <arm_group_label>Endovenous hydratation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline endovenous hydratation</intervention_name>
    <description>If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.</description>
    <arm_group_label>Endovenous hydratation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes over 18 years

          -  Candidates for a study with computed tomography and intravenous contrast

          -  A glomerular filtration rate between 30 and 45 mL / min including both determinations

          -  They have signed the written informed consent after being informed of the objectives
             and the nature of the case or be unable to have the authorization or agreement of its

        Exclusion Criteria:

          -  refuse to participate in the study

          -  pregnancy or lactation

          -  Other risk factors for Contrast Induced Nephropathy: diabetes mellitus, have an age of
             70 years or above, heart failure (defined by a scale New York Heart Association 3 or
             4), hypotension (defined as systolic blood pressure &lt;100), being treated with
             nephrotoxic medications.

          -  Any disease or a history that, in the investigator's opinion, could confound the
             results of the study or pose an additional risk to patient treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Garcia Cinca, Bch</last_name>
    <phone>+34 93 227 54 00</phone>
    <phone_ext>4199</phone_ext>
    <email>dgarcia@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Carmen Sebastià, PhD</last_name>
      <phone>+34 93 227 54 00</phone>
    </contact>
    <investigator>
      <last_name>Maria Carmen Sebastià, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>David Garcia Cinca</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>renal insufficiency</keyword>
  <keyword>computed tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

